Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors
JL Woodhead, WJ Brock, SE Roth… - Toxicological …, 2017 - academic.oup.com
Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries
for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD…
for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD…
Editor's highlight: Candidate risk factors and mechanisms for tolvaptan-induced liver injury are identified using a collaborative cross approach
M Mosedale, Y Kim, WJ Brock, SE Roth… - Toxicological …, 2017 - academic.oup.com
Clinical trials of tolvaptan showed it to be a promising candidate for the treatment of
Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for …
Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for …
[HTML][HTML] Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal …
…, VE Torres, H Li, W Wang, ME Hoke, SE Roth… - American Journal of …, 2023 - Elsevier
Rationale & Objective Tolvaptan is associated with risk of drug-induced liver injury when
used to treat autosomal dominant polycystic kidney disease (ADPKD). After this risk was …
used to treat autosomal dominant polycystic kidney disease (ADPKD). After this risk was …
miR-122 release in exosomes precedes overt tolvaptan-induced necrosis in a primary human hepatocyte micropatterned coculture model
…, SR Khetani, J Lu, WJ Brock, SE Roth… - Toxicological …, 2018 - academic.oup.com
Idiosyncratic drug-induced liver injury (IDILI) is thought to often result from an adaptive immune
attack on the liver. However, it has been proposed that the cascade of events culminating …
attack on the liver. However, it has been proposed that the cascade of events culminating …
Next‐generation DILI biomarkers: prioritization of biomarkers for qualification and best practices for biospecimen collection in drug development
SE Roth, MI Avigan, D Bourdet, D Brott… - Clinical …, 2020 - Wiley Online Library
The diagnosis and management of drug‐induced liver injury ( DILI ) remains a challenge in
clinical trials in drug development. The qualification of emerging biomarkers capable of …
clinical trials in drug development. The qualification of emerging biomarkers capable of …
Bile acids as potential biomarkers to assess liver impairment in polycystic kidney disease
Polycystic kidney disease is characterized by the progressive development of kidney cysts
and declining renal function with frequent development of cysts in other organs including the …
and declining renal function with frequent development of cysts in other organs including the …
Altered expression and function of hepatic transporters in a rodent model of polycystic kidney disease
J Bezençon, JJ Beaudoin, K Ito, D Fu, SE Roth… - Drug Metabolism and …, 2019 - ASPET
Autosomal dominant polycystic kidney disease (ADPKD) is a common form of inherited
polycystic kidney disease (PKD) and is a leading cause of kidney failure. Fluid-filled cysts …
polycystic kidney disease (PKD) and is a leading cause of kidney failure. Fluid-filled cysts …
Altered hepatobiliary disposition of tolvaptan and selected tolvaptan metabolites in a rodent model of polycystic kidney disease
…, J Bezençon, Y Cao, K Mizuno, SE Roth… - Drug Metabolism and …, 2019 - ASPET
Tolvaptan, a vasopressin V 2 -receptor antagonist, has demonstrated efficacy in slowing
kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD)…
kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD)…
Simultaneous quantitation of delamanid (OPC-67683) and its eight metabolites in human plasma using UHPLC–MS/MS
…, B Johnston, S Carter, J Brisson, SE Roth - … of Chromatography B, 2015 - Elsevier
Delamanid (OPC-67683) is a novel nitro-dihydroimidazo-oxazole derivative that is being
developed by Otsuka Pharmaceutical Co., Ltd., Japan (referred to as Otsuka hereafter) for the …
developed by Otsuka Pharmaceutical Co., Ltd., Japan (referred to as Otsuka hereafter) for the …
Peptide-mediated delivery of siRNA via noncovalent complexes and covalent conjugates
…, L Chen, Y Chen, K Cui, KW Farber, SE Roth… - … Biology Using Peptides …, 2006 - Springer
Improving the intracellular delivery of synthetic oligonucleotides and their analogs is an
important goal in the development of small interfering RNA (siRNA) therapeutics for affecting …
important goal in the development of small interfering RNA (siRNA) therapeutics for affecting …